Are small caps an option in the upcoming bear market?

Published 08-APR-2019 12:08 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Fresh pain is on the way for investors warns Jamie Dimon, CEO of JPMorgan Chase & Co., the largest bank in the US.

In his annual report to shareholders, Dimon suggests that investors should brace for a downturn.

His pessimism follows last year’s correction when the ASX 200 lost 14% between late August and late December and, in the US, the S&P 500 lost 19.8% in the fourth quarter, just toeing the line above entering a technical bear market.

Markets have largely bounced back since, but don’t get too comfortable: Dimon speculates that “The fourth quarter of 2018 might be a harbinger of things to come”.

Assuming he’s on the ball — although there are no certainties in the markets — what does that means for small cap investors?

The performance of ‘small caps’, as a class, can be viewed as a magnified reflection of the wider market’s health. As small caps tend to be more volatile, they experience larger share price fluctuations — meaning the potential for larger gains and, conversely, larger losses.

This was shown last year when the leading US small cap index, the Russell 2000, lost more than 27% from peak to trough in the August-December period mentioned above.

If we do see another downturn in the near term I would expect a similar scenario. But that doesn’t mean that small caps aren’t your best bet.

But rather than worrying about the performance of a small cap index, or diversified fund, it will pay to be more selective. Seek out those with the best chances of success — and avoid the rest.

A couple of locally listed juniors that I’ve been looking at this week are an example of this...

Digital ag-tech company CropLogic Ltd (ASX: CLI) is up 32% this week alone and 200% since February. What’s key here is recognising how the company has set itself up to leverage structural changes, seeking to capitalise on changing US cannabis legislation backed by its agronomy expertise and agricultural technologies.

Leigh Creek (ASX: LCK) is another that has emerged as an outperformer, gaining close to 240% since February. The emerging energy company had the reserves at its project in South Australia certified last week — a historic milestone that confirms it as one of Eastern Australia’s largest undeveloped and uncontracted gas reserves. And is comes right as Eastern Australian gas consumers face an energy crisis.

When considering companies like these, you can almost completely ignore the wider market. Instead focus on drivers such the industry’s outlook, the experience and expertise of the company’s management, and the quality of its assets or project.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X